185 related articles for article (PubMed ID: 15531928)
41. KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells.
Marreiros A; Dudgeon K; Dao V; Grimm MO; Czolij R; Crossley M; Jackson P
Oncogene; 2005 Jan; 24(4):637-49. PubMed ID: 15580298
[TBL] [Abstract][Full Text] [Related]
42. Generation of p53 target database via integration of microarray and global p53 DNA-binding site analysis.
Liu S; Mirza A; Wang L
Methods Mol Biol; 2004; 281():33-54. PubMed ID: 15220520
[TBL] [Abstract][Full Text] [Related]
43. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
44. Cloning and characterization of a novel gene PDRG that is differentially regulated by p53 and ultraviolet radiation.
Luo X; Huang Y; Sheikh MS
Oncogene; 2003 Oct; 22(46):7247-57. PubMed ID: 14562055
[TBL] [Abstract][Full Text] [Related]
45. SIRF--a novel regulator element controlling transcription from the p55Cdc/Fizzy promoter during the cell cycle.
Haugwitz U; Tschöp K; Engeland K
Biochem Biophys Res Commun; 2004 Jul; 320(3):951-60. PubMed ID: 15240141
[TBL] [Abstract][Full Text] [Related]
46. The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53.
Strauss BE; Shivakumar C; Deb SP; Deb S; Haas M
Biochem Biophys Res Commun; 1995 Dec; 217(3):825-31. PubMed ID: 8554604
[TBL] [Abstract][Full Text] [Related]
47. Mitofusin-2 is a novel direct target of p53.
Wang W; Cheng X; Lu J; Wei J; Fu G; Zhu F; Jia C; Zhou L; Xie H; Zheng S
Biochem Biophys Res Commun; 2010 Oct; 400(4):587-92. PubMed ID: 20804729
[TBL] [Abstract][Full Text] [Related]
48. A novel p53-inducible gene coding for a microtubule-localized protein with G2-phase-specific expression.
Utrera R; Collavin L; Lazarević D; Delia D; Schneider C
EMBO J; 1998 Sep; 17(17):5015-25. PubMed ID: 9724637
[TBL] [Abstract][Full Text] [Related]
49. p53 and cell-cycle control: a finger in every pie.
North S; Hainaut P
Pathol Biol (Paris); 2000 Apr; 48(3):255-70. PubMed ID: 10858958
[TBL] [Abstract][Full Text] [Related]
50. wt p53 dependent expression of a membrane-associated isoform of adenylate kinase.
Collavin L; Lazarevic D; Utrera R; Marzinotto S; Monte M; Schneider C
Oncogene; 1999 Oct; 18(43):5879-88. PubMed ID: 10557075
[TBL] [Abstract][Full Text] [Related]
51. Mitosis-independent survivin gene expression in vivo and regulation by p53.
Xia F; Altieri DC
Cancer Res; 2006 Apr; 66(7):3392-5. PubMed ID: 16585159
[TBL] [Abstract][Full Text] [Related]
52. Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53.
Ueda K; Arakawa H; Nakamura Y
Oncogene; 2003 Aug; 22(36):5586-91. PubMed ID: 12944906
[TBL] [Abstract][Full Text] [Related]
53. Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves protein-protein interaction with tumor suppressor p53.
Nandi AK; Ford T; Fleksher D; Neuman B; Rapoport AP
Biochem Biophys Res Commun; 2007 Jun; 358(1):181-8. PubMed ID: 17482142
[TBL] [Abstract][Full Text] [Related]
54. E2FBP1/DRIL1, an AT-rich interaction domain-family transcription factor, is regulated by p53.
Ma K; Araki K; Ichwan SJ; Suganuma T; Tamamori-Adachi M; Ikeda MA
Mol Cancer Res; 2003 Apr; 1(6):438-44. PubMed ID: 12692263
[TBL] [Abstract][Full Text] [Related]
55. Further characterisation of the p53 responsive element--identification of new candidate genes for trans-activation by p53.
Bourdon JC; Deguin-Chambon V; Lelong JC; Dessen P; May P; Debuire B; May E
Oncogene; 1997 Jan; 14(1):85-94. PubMed ID: 9010235
[TBL] [Abstract][Full Text] [Related]
56. Absence of p53-dependent cell cycle regulation in pluripotent mouse cell lines.
Schmidt-Kastner PK; Jardine K; Cormier M; McBurney MW
Oncogene; 1998 Jun; 16(23):3003-11. PubMed ID: 9662333
[TBL] [Abstract][Full Text] [Related]
57. p53 is involved in the p120E4F-mediated growth arrest.
Sandy P; Gostissa M; Fogal V; Cecco LD; Szalay K; Rooney RJ; Schneider C; Del Sal G
Oncogene; 2000 Jan; 19(2):188-99. PubMed ID: 10644996
[TBL] [Abstract][Full Text] [Related]
58. Identification of beta1,4GalT II as a target gene of p53-mediated HeLa cell apoptosis.
Zhou J; Wei Y; Liu D; Ge X; Zhou F; Jiang XY; Gu J
J Biochem; 2008 Apr; 143(4):547-54. PubMed ID: 18211920
[TBL] [Abstract][Full Text] [Related]
59. The H19 TATA-less promoter is efficiently repressed by wild-type tumor suppressor gene product p53.
Dugimont T; Montpellier C; Adriaenssens E; Lottin S; Dumont L; Iotsova V; Lagrou C; Stéhelin D; Coll J; Curgy JJ
Oncogene; 1998 May; 16(18):2395-401. PubMed ID: 9620557
[TBL] [Abstract][Full Text] [Related]
60. Activated p53 suppresses the histone methyltransferase EZH2 gene.
Tang X; Milyavsky M; Shats I; Erez N; Goldfinger N; Rotter V
Oncogene; 2004 Jul; 23(34):5759-69. PubMed ID: 15208672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
